GlassScriptPhysician profile
Michael Rosenzweig
NPI 1164470126
$109,505.32
in general payments reported to CMS, 2019-2025
18 companies · $1,806 in 2025
The $1,806 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $32K · 2021: $16K · 2022: $21K · 2023: $2,446 · 2024: $344 · 2025: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,333 · Food and Beverage: $2,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,332.50 |
| Food and Beverage | $2,263.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $38,839.56 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $24,903.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17,225.83 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $7,114.93 | 2022-2023 | |
| Akcea Therapeutics, INC. | $6,761.78 | 2019-2020 | |
| Genzyme Corporation | $4,732.00 | 2019 | |
| Genentech, INC. | $4,425.55 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $2,142.58 | 2020-2023 | Tecvayli |
| F. Hoffmann-La Roche Ag | $1,605.08 | 2019 | |
| Janssen Research & Development, LLC | $934.29 | 2021-2025 | Darzalex |
| Amgen INC. | $286.49 | 2022-2023 | Kyprolis, Blincyto |
| Alnylam Pharmaceuticals INC. | $202.79 | 2024-2025 | Onpattro, Amvuttra |
| Pfizer INC. | $167.72 | 2023 | |
| Sanofi-Aventis U.S. LLC | $112.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.37 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $20.94 | 2023 | Ultomiris |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosenzweig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.